✦ LIBER ✦

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127

✍ Scribed by Marion G. Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L. Brosgart; Jeffrey M. Jacobson; Victoria A. Johnson; Richard B. Pollard; James F. Rooney; Kenneth E. Sherman; Susan Swindells; Bruce Polsky; ACTG Protocol A5127 Team

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 152 KB
Volume: 44
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21388

No coin nor oath required. For personal study only.

✦ Synopsis

Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in subjects coinfected with HIV. Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment of HIV-1 and HBV infection, respectively, but both have in vivo and in vitro activity against HBV. This study evaluated the anti-HBV activity of TDF compared to ADV in HIV/HBV-coinfected subjects. ACTG A5127 was a prospective randomized, double-blind, placebo-controlled trial of daily 10 mg of ADV versus 300 mg of TDF in subjects with HBV and HIV coinfection on stable ART, with serum HBV DNA >/= 100,000 copies/mL, and plasma HIV-1 RNA

📜 SIMILAR VOLUMES

Comparison of adefovir and tenofovir in

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

✍ Florian van Bömmel; Thomas Wünsche; Stefan Mauss; Petra Reinke; Alexandra Bergk; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Adefovir dipivoxil was recently approved for the treatment of wild-type and lamivudineresistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of adefovir that is used in the treatment of HIV infected patients, has recently been shown to also be effective in patients w

Early hepatitis B virus DNA reduction in

Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

✍ Nancy Leung; Cheng-Yuan Peng; Hie-Won Hann; Jose Sollano; Judy Lao-Tan; Chao-Wei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA of 10(8) copi

Controlled clinical trial of acyclovir i

Controlled clinical trial of acyclovir in chronic hepatitis B virus infection

✍ Dr. Graeme J. M. Alexander; Elizabeth A. Fagan; John E. Hegarty; Adrian L. W. F. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 470 KB 👁 1 views

A randomised, controlled trial comparing acyclovir, 45 mg/kg/day as a continuous IV infusion for 28 days, with no other therapy, was carried out in 30 stable HBsAg carriers seropositive for HBeAg for more than 6 months. Twenty-eight had hepatitis B virus DNA-polymerase activity and/or hepatitis B vi

Lymphoblastoid interferon in controlled

Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection

✍ Stephanos J. Hadziyannis 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB 👁 2 views

Efficacy and safety of entecavir versus

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

✍ Yun-Fan Liaw; Maria Raptopoulou-Gigi; Hugo Cheinquer; Shiv Kumar Sarin; Tawesak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB 👁 2 views

A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up

Hepatitis B and C virus infection, alcoh

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy

✍ F Donato; A Tagger; R Chiesa; M L Ribero; V Tomasoni; M Fasola; U Gelatti; G Por 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

FOR THE BRESCIA HCC STUDY risk (RR) estimates for these factors. The relationships be-We performed a case-control study to assess the association tween HBV and HCV infections, and between these infections of hepatocellular carcinoma (HCC) with hepatitis B virus and alcohol drinking, may be of releva